var data={"title":"Factor VIIa (activated), recombinant human: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor VIIa (activated), recombinant human: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6171?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-viia-activated-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor VIIa (activated), recombinant human: Patient drug information&quot;</a> and <a href=\"topic.htm?path=factor-viia-activated-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Factor VIIa (activated), recombinant human: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10053630\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thrombosis: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious arterial and venous thrombotic events following administration of Factor VIIa (recombinant) have been reported. Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive Factor VIIa (recombinant). Monitor patients for signs and symptoms of activation of the coagulation system and for thrombosis. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169443\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>NovoSeven RT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169444\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Niastase;</li>\n      <li>Niastase RT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169459\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169445\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital hemophilia A or B with inhibitors:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bleeding episodes:</i> 90 mcg/kg/dose every 2 hours until hemostasis is achieved or until the treatment is judged ineffective. Doses between 35 and 90 mcg/kg/dose have been used successfully in clinical trials. The dose, interval, and duration of therapy may be adjusted based upon the severity of bleeding and the degree of hemostasis achieved. For patients experiencing severe bleeds, dosing should be continued at 3- to 6-hour intervals post-hemostasis. The duration of any post-hemostatic dosing should be minimized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Perioperative management:</i> 90 mcg/kg/dose immediately before surgery (additional bolus doses may be administered for major surgery if required); repeat at 2-hour intervals for the duration of surgery. For minor surgery, continue 90 mcg/kg/dose postoperatively every 2 hours for 48 hours, then every 2 to 6 hours until healed. For major surgery, continue 90 mcg/kg/dose postoperatively every 2 hours for 5 days, then every 4 hours until healed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital factor VII deficiency:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bleeding episodes:</i> 15 to 30 mcg/kg/dose every 4 to 6 hours until hemostasis is achieved. Doses as low as 10 mcg/kg have been effective.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Perioperative management:</i> 15 to 30 mcg/kg/dose immediately before surgery; repeat every 4 to 6 hours for the duration of surgery and until hemostasis achieved. Doses as low as 10 mcg/kg have been effective.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acquired hemophilia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bleeding episodes:</i> 70 to 90 mcg/kg/dose every 2 to 3 hours until hemostasis is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Perioperative management:</i> 70 to 90 mcg/kg/dose immediately before surgery; repeat every 2 to 3 hours for the duration of surgery and until hemostasis achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glanzmann&rsquo;s thrombasthenia: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Bleeding episodes</i> (severe, refractory to platelet transfusions): 90 mcg/kg/dose every 2 to 6 hours until hemostasis is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Perioperative management:</i> 90 mcg/kg/dose immediately before surgery; repeat at 2-hour intervals for the duration of surgery. Continue 90 mcg/kg/dose every 2 to 6 hours to prevent postoperative bleeding. <b>Note:</b> Higher average infused doses (median 100 mcg/kg) were noted for surgical patients who had clinical refractoriness with or without platelet-specific antibodies compared to those with neither.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracranial hemorrhage associated with danaparoid (off-label use): </b>IV: 90 mcg/kg once (NCS/SCCM [Frontera 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Refractory bleeding after cardiac surgery in nonhemophiliac patients (off-label use):</b> Dosing not established; doses in the range of 35 to 70 mcg/kg/dose have been recommended based on low-quality evidence (case series, observational studies) (Chapman 2011; Ferraris 2011; Karkouti 2007); in patients with a left ventricular assist device, lower doses (ie, 10 to 20 mcg/kg) may be preferred to reduce thromboembolic events (Bruckner 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169454\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=factor-viia-activated-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Factor VIIa (activated), recombinant human: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital factor VII deficiency:</b> Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glanzmann&rsquo;s thrombasthenia:</b> Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital hemophilia A or B with inhibitors:</b> Children and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169446\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881412\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided the in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881413\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169430\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovoSeven RT: 1 mg (1 ea); 2 mg (1 ea); 5 mg (1 ea); 8 mg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169417\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169432\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV administration only as a bolus over 2 to 5 minutes (depending on the dose administered). Use NS to flush line (if necessary) before and after administration. Administer within 3 hours after reconstitution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169431\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Bleeding episodes and perioperative management:</b> Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, and Glanzmann&rsquo;s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets; treatment of bleeding episodes and perioperative management in adults with acquired hemophilia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474640\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Intracranial hemorrhage associated with danaparoid; Refractory bleeding after cardiac surgery in nonhemophiliac patients; Warfarin-related intracerebral hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169423\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Thrombosis (4%), hypertension (2%), bradycardia (1%), edema (1%), hypotension (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Cerebrovascular disease (&lt;2%), headache (1%), pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus (1%), skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Decreased serum fibrinogen (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Vomiting (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Decreased prothrombin time (1%), disseminated intravascular coagulation (1%), increased fibrinolysis (1%),  purpura (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Abnormal hepatic function tests (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Osteoarthrosis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Renal function abnormality (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Pneumonia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (4%), decreased therapeutic response (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylaxis, angina pectoris, angioedema, antibody development, arterial embolism (retinal), arterial thrombosis, arterial thrombosis (limb, retinal), arthralgia bowel infarction, cerebral infarction, cerebral ischemia, cerebrovascular accident, deep vein thrombosis, flushing, hepatic artery thrombosis, hypersensitivity, immunogenicity, increased fibrin degradation products (including D-dimer elevation), intracardiac thrombus, local phlebitis, myocardial infarction, myocardial ischemia, nausea, occlusion of cerebral arteries, pain at injection site, peripheral ischemia, portal vein thrombosis, pulmonary embolism, renal artery thrombosis, shock, thrombophlebitis, urticaria, venous thrombosis at injection site  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169435\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to eptacog alfa, any component of the formulation, or mouse, hamster or bovine protein</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169420\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody formation: In patients with factor VII deficiency, if factor VIIa activity does not reach the expected level, prothrombin time is not corrected, or bleeding is uncontrolled (with recommended doses), suspect antibody formation and perform antibody analysis. Prothrombin time and factor VII coagulant activity should be measured before and after administration in patients with factor VII deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported with use. Use with caution in patients with known hypersensitivity to mouse, hamster, or bovine proteins, or factor VIIa, or any components of the product. If hypersensitivity reaction occurs, discontinue use and administer appropriate treatment; carefully consider the benefits versus the risk of continued treatment with factor VIIa.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Serious arterial and venous thrombotic events following administration of Factor VIIa (recombinant) have been reported. Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive factor VIIa (recombinant). Monitor patients for signs and symptoms of activation of the coagulation system and for thrombosis.</b> All patients receiving factor VIIa should be monitored for signs and symptoms of activation of the coagulation system or thrombosis; thrombotic events may be increased due to circulating tissue factor or predisposing coagulopathy in patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, septicemia, crush injury, concomitant treatment with activated or nonactivated prothrombin complex concentrates, or uncontrolled postpartum hemorrhage. Use with caution in patients with an increased risk of thromboembolic complications (eg, coronary heart disease, liver disease, DIC, postoperative immobilization, elderly patients, and neonates). Decreased dosage or discontinuation is warranted with confirmed intravascular coagulation or presence of clinical thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens).  Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Reduced efficacy: A number of factors influence the efficacy of factor VIIa, including hypothermia, thrombocytopenia, acidosis, and the amount of blood products transfused prior to administration (Dunkley, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299309\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220313\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10155&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIIa (Recombinant).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor XIII A-Subunit (Recombinant): May enhance the thrombogenic effect of Factor VIIa (Recombinant).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2181984\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Factor VII concentrations may vary significantly in pregnant women with coagulation disorders. Pregnant women with hemophilia should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Recombinant factor VIIa is recommended for the management of bleeding disorders in pregnant women with factor VII deficiency. Prophylaxis at delivery may be needed if factor VII concentrations are &lt;10 to 20 units /dL or in women with a significant bleeding history and treatment should continue for 3 to 5 days postpartum depending on route of delivery. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16354807\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if factor VIIa (recombinant) is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends that a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169436\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169428\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for evidence of hemostasis and thrombosis (including laboratory confirmation of intravascular coagulation, if appropriate). Although the prothrombin time (PT)/INR, aPTT, and factor VII clotting activity have shown no direct correlation with achieving hemostasis, these parameters may be useful as adjunct tests to evaluate efficacy and guide dose or interval adjustments. In factor VII&ndash;deficient patients, monitor PT and factor VII clotting activity before and after administration; if the factor VIIa activity fails to reach the expected level, if PT is not corrected, or if bleeding is not controlled after treatment with recommended doses, monitor for factor VII antibodies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169419\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Recombinant factor VIIa, a vitamin K-dependent glycoprotein, promotes hemostasis by activating the extrinsic pathway of the coagulation cascade. It replaces deficient activated coagulation factor VII, which complexes with tissue factor and may activate coagulation factor X to Xa and factor IX to IXa. When complexed with other factors, coagulation factor Xa converts prothrombin to thrombin, a key step in the formation of a fibrin-platelet hemostatic plug.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169434\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemophilia A or B:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Distribution: V<sub>ss</sub>: Children 2 to 12 years: 164 mL/kg; Adults: 107 to 128 mL/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Half-life, terminal: Children 2 to 12 years: 2.6 hours; Adults: 2.9 to 3.1 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Excretion: Clearance: Children 2 to 12 years: 58 mL/hour/kg; Adults: 31 to 39 mL/hour/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Factor VII deficiency:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Distribution: V<sub>ss</sub>: 280 to 290 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Half-life, terminal: 2.8 to 3.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Excretion: Clearance: 71 to 79 mL/kg/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323142\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (NovoSeven RT Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (0 Price provided is per microgram): $2.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (0 Price provided is per microgram): $2.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (0 Price provided is per microgram): $2.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (0 Price provided is per microgram): $2.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169437\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Novonordisk (MX);</li>\n      <li>NovoSeven (AE, AR, AT, BE, BG, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IS, IT, JO, KR, KW, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PE, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UA, UY);</li>\n      <li>Novoseven (MX);</li>\n      <li>Novoseven RT (AU, CR, CU, DO, GT, HN, NI, PA, SV, VN);</li>\n      <li>NovoSeven RT (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bruckner BA, DiBardino DJ, Ning Q, et al, &quot;High Incidence of Thromboembolic Events in Left Ventricular Assist Device Patients Treated With Recombinant Activated Factor VII,&quot; <i>J Heart Lung Transplant</i>, 2009, 28(8):785-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/19632574/pubmed\" target=\"_blank\" id=\"19632574\">19632574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21601468\"></a>Chapman AJ, Blount AL, Davis AT, et al, &quot;Recombinant Factor VIIa (NovoSeven RT) Use in High Risk Cardiac Surgery,&quot; <i>Eur J Cardiothorac Surg</i>, 2011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/21601468/pubmed\" target=\"_blank\" id=\"21601468\">21601468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunkley S, Phillips L, McCall P, et al. Recombinant activated factor VII in cardiac surgery: Experience from the Australian and New Zealand Haemostasis Registry. <i>Ann Thorac Surg</i>. 2008;85:836-844.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferraris VA, Brown JR Despotis GJ, et al, &quot;2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines,&quot; <i>Ann Thorac Surg</i>, 2011, 91(3):944-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/21353044/pubmed\" target=\"_blank\" id=\"21353044\">21353044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15595332\"></a>Freeman WD, Brott TG, Barrett KM, et al, &ldquo;Recombinant Factor VIIa for Rapid Reversal of Warfarin Anticoagulation in Acute Intracranial Hemorrhage,&rdquo; <i>Mayo Clin Proc</i>, 2004, 79(12):1495-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/15595332/pubmed\" target=\"_blank\" id=\"15595332\">15595332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016; 24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18617125\"></a>Ilyas C, Beyer GM, Dutton RP, et al, &ldquo;Recombinant Factor VIIa for Warfarin-Associated Intracranial Bleeding,&rdquo; <i>J Clin Anesth</i>, 2008, 20(4):276-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/18617125/pubmed\" target=\"_blank\" id=\"18617125\">18617125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17602044\"></a>Karkouti K, Beattie WS, Crowther MA, et al, &quot;The Role of Recombinant Factor VIIa in On-Pump Cardiac Surgery: Proceedings of the Canadian Consensus Conference,&quot; <i>Can J Anaesth</i>, 2007, 54(7):573-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/17602044/pubmed\" target=\"_blank\" id=\"17602044\">17602044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al; UK Haemophilia Centre Doctors' Organization. The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayer SA, Brun NC, Begtrup K, et al, &ldquo;Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage,&rdquo; <i>N Engl J Med</i>, 2008, 358(20):2127-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/18480205/pubmed\" target=\"_blank\" id=\"18480205\">18480205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mayer SA, Brun NC, Begtrup K, et al, &ldquo;Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage,&rdquo; <i>N Engl J Med</i>, 2005, 352(8):777-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/15728810/pubmed\" target=\"_blank\" id=\"15728810\">15728810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohr AM, Holcomb JB, Dutton RP, et al, &ldquo;Recombinant Activated Factor VIIa and Hemostasis in Critical Care: A Focus on Trauma,&rdquo; <i>Crit Care</i>, 2005, 9 (Suppl 5):37-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/15693982/pubmed\" target=\"_blank\" id=\"15693982\">15693982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NiaStase RT (factor VIIa) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NovoSeven RT (factor VIIa) [prescribing information]. Plainsboro, NJ: Novo Nordisk; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viia-activated-recombinant-human-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10155 Version 122.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F10053630\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169443\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F169444\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F169459\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F169445\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F169454\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F169446\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15881412\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881413\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169430\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F169417\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F169432\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F169431\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474640\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169423\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169435\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169420\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299309\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220313\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2181984\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16354807\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F169436\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F169428\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169419\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F169434\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323142\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F169437\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10155|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-viia-activated-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">Factor VIIa (activated), recombinant human: Patient drug information</a></li><li><a href=\"topic.htm?path=factor-viia-activated-recombinant-human-pediatric-drug-information\" class=\"drug drug_pediatric\">Factor VIIa (activated), recombinant human: Pediatric drug information</a></li></ul></div></div>","javascript":null}